1. Inicio
  2. Publicaciones
  3. Treatment patterns and outcomes in secondary acute myeloid leukemia arising after hypomethylating agents: PETHEMA registry study

Treatment patterns and outcomes in secondary acute myeloid leukemia arising after hypomethylating agents: PETHEMA registry study

Fecha de publicación:

Autores de IIS La Fe

Participantes ajenos a IIS La Fe

  • Martínez-López, J
  • Bergua, J
  • Arboli, ER
  • Labrador, J
  • Sossa, C
  • Gil, C
  • Algarra, L
  • Lavilla-Rubira, E
  • Serrano, J
  • de Rueda, B
  • Ibañez, F
  • González, BJG
  • Amigo, ML
  • Belmonte, DG
  • Rodríguez-Medina, C
  • Gómez-Roncero, MI
  • Colorado, M
  • Lorenzo, JLL
  • Tormo, M
  • Fernández, OA
  • Foncillas, MA
  • Pierola, AA
  • Vives, S
  • Núñez, MV
  • López-Vidal, H
  • Pérez-Santaolalla, E
  • Ramos, LH
  • Boyero, RG
  • González, LL
  • Roldán, A
  • Calderón, SC
  • Infante, JB
  • Olave, T
  • García-Suárez, J
  • de Laiglesia, A
  • Trigo, F

Grupos

Abstract

Background: Patients with secondary acute myeloid leukemia who previously received hypomethylating agents for prior myeloid neoplasms (HMA-sAML) face a dismal prognosis. Methods: The authors analyze the characteristics, therapeutic approaches, and outcomes of patients with HMA-sAML from the Programa Espa & ntilde;ol para el Tratamiento de Hemopat & iacute;as Malignas (PETHEMA) registry. Results: A total of 479 patients were included, mostly from prior myelodysplastic syndrome (84%). Frontline therapy consisted of intensive chemotherapy (IC) in 31%, low-dose cytarabine-based in 19%, supportive care and clinical trial 17% each, and HMA-based therapy in 12% and 4% in venetoclax-based regimen. Complete remission was achieved in 95 patients (27%), with higher rate among IC and venetoclax-based groups (44% and 41%, respectively). The median overall survival (OS) was 4.93 months, with 7.68 months for IC patients, 7.82 months after HMA monotherapy, and 4.66 months after venetoclax-based regimens. Patients who underwent allogeneic hematopoietic stem cell transplantation in first remission (n = 33, 9%) had a better survival outcome (median OS not reached). Multivariate analyses identified age (>= 65 years), Eastern Cooperative Oncology Group >2, higher white blood cell count, and adverse risk cytogenetic as adverse prognostic factors, whereas NPM1 mutation was a favorable factor. Conclusions: Patients with HMA-sAML have a poor prognosis and suboptimal outcomes with conventional treatments, including BCL2 inhibitors, highlighting the need for clinical trials targeting this population.

© 2025 American Cancer Society.

Datos de la publicación

ISSN/ISSNe:
0008-543X, 1097-0142

CANCER  WILEY

Tipo:
Article
Páginas:
-
PubMed:
39748608
Enlace a otro recurso:
www.scopus.com
Factor de Impacto:
2,463 SCImago ℠
Cuartil:
Q1 SCImago ℠

Citas Recibidas en Web of Science: 4

Documentos

  • No hay documentos

Métricas

Filiaciones mostrar / ocultar

Keywords

  • acute myeloid leukemia; hypomethylating agents; myelodysplastic syndrome; outcomes; secondary AML

Cita

Compartir